Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma 
INTRODUCTION
Low skeletal muscle mass has been associated with worse outcomes following surgery for malignancies of gastrointestinal origin. [1] [2] [3] [4] [5] It has been shown to affect postoperative morbidity and mortality in patients with colorectal liver metastases, 3 hepatocellular carcinoma 6 and colorectal cancer 4 as well as long-term survival following resection of hepatocellular carcinoma, 1, 6 pancreatic cancer 2 and colorectal liver metastases. 5 In these studies, low or high body mass index was not a risk factor for poor outcomes. These results suggest that lower skeletal muscle mass might reflect frailty and may be a highly relevant risk factor in preoperative risk assessment. Measurement of the total skeletal muscle area at the third lumbar vertebra on computed tomography (CT) images has widely been accepted as a standard tool to determine whole body skeletal muscle mass in the preoperative workup. [7] [8] [9] Perihilar cholangiocarcinoma (PHC) is a biliary tumor located at the liver hilum, which typically requires a combined extrahepatic bile duct and liver resection in case of resectable disease. Several studies have shown that an aggressive surgical approach has improved the R0 resection rate and survival. 10, 11 However, liver resection in PHC is associated with high risks of morbidity and mortality, as reported up to 68% and 14%, respectively. [10] [11] [12] [13] Identification of potentially reversible risk factors might allow us to modify these risks preoperatively. The aim of this study was to investigate the impact of low skeletal muscle mass on postoperative morbidity, mortality and overall survival following resection of PHC.
METHODS
Data were retrospectively collected from a database including all patients submitted to exploratory laparotomy for PHC between 1998 and 2013 in a single institution (Academic Medical Centre, Amsterdam). Inclusion criteria required patients to have undergone curative-intent major hepatectomy and necessitated the availability of adequate preoperative CT images of the abdomen. The latter are necessary for skeletal muscle mass measurement. Study variables included patient characteristics, laboratory results, tumor characteristics (Bismuth-Corlette classification and histopathological information), details of surgery, complications, and overall survival and recurrence data.
Preoperative measurement of skeletal muscle mass
In all patients, CT scans selected for analysis were performed after adequate preoperative biliary drainage (if indicated) was achieved as part of the routine preoperative workup. Cross-sectional skeletal muscle surface (cm 2 ) assessment was assessed at the level of the third lumbar vertebra (L3) on two consecutive axial slices with visible vertebral spine, as previously described. 14 Plain images were selected by an experienced staff radiologist (CYN) and measurements were performed using OsiriX version 5.8 (32-bit; http://www.osirix-viewer.com) by one of the authors (RJSC. Using a Hounsfield units (HU) range of -30HU to +110HU to distinguish skeletal muscle tissue, measurements of the psoas, paraspinal, transverse abdominal, internal and external oblique and rectus abdominis muscles were obtained (Figure 1) . Obtained cross-sectional areas of the two L3 levels were then averaged and corrected for height to calculate the L3 muscle index expressed in cm 2 /m 2 . A previous study has demonstrated a very good inter-observer variability. 4 Weight loss was calculated by subtracting the patient's weight at the time of diagnosis from his or her reported weight prior to illness. The presence of weight loss was then defined as a >2% loss from pre-illness self-reported stable weight. . Skeletal muscle area highlighted in red. 1, rectus abdominis; 2, external oblique; 3, internal oblique; 4, transverse abdominal; 5, psoas; 6, paraspinal.
Surgical procedures
Prior to surgery, patients underwent endoscopic biliary drainage and/or percutaneous drainage when indicated because of jaundice and dilatation of the bile ducts in the future remnant liver.
Preoperative liver function was assessed with CT volumetry and 99m Tc-mebrofenin hepatobiliary scintigraphy. 15 Patients underwent radical resection of the tumor encompassing hilar resection with en bloc (extended) hemi-hepatectomy including the caudate lobe, excision of the portal vein bifurcation when involved and complete lymphadenectomy of the hepatoduodenal ligament in the majority of cases. For biliary reconstruction, end-to-side anastomoses of the segmental ducts and a
Roux-en-Y jejunal loop were constructed. 10 Resections were performed by two staff surgeons with extensive hepatobiliary expertise.
Definitions of complications
Postoperative morbidity was defined as any severe complication (i.e. Clavien-Dindo Grade III or higher) 16 within 30 days after surgery. Overall complications were further stratified into postoperative haemorrhage, anastomotic leakage, intra-abdominal abscess or fluid collections, and acute liver failure, using previously described definitions.
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Haemorrhage was defined as a drop in haemoglobin level of >3 g/dl after the end of surgery compared with the postoperative baseline level and/or any postoperative transfusion of packed red blood cells for a falling haemoglobin level and/or the need for invasive re-intervention (e.g. embolization or relaparotomy) to stop bleeding. 17 Anastomotic leakage was defined as fluid with an increased bilirubin concentration in the abdominal drain (three times greater than serum bilirubin concentration) on or after postoperative day (PoD) 3 or the need for radiologic intervention because of contrast leakage during percutaneous transhepatic cholangiography (in the event of hepaticojejunostomy leakage) 18 or a defect of the intestinal wall at the anastomotic site leading to a communication between the intra-and extraluminal compartments (in the event of enteroenterostomy leakage). 19 
Follow-up
No adjuvant chemotherapy was administered after initial curative resection. Clinical follow-up was performed routinely every 3 months in the first year after surgery and every 6 months throughout the following 5 years. Laboratory tests and follow-up CT scans were performed in the first 6 months to detect early recurrence and later as indicated. The overall survival status of patients discharged from further follow-up was examined by checking the municipal records database.
Statistical analysis
The variable of skeletal muscle mass was dichotomized using optimal stratification to allow for risk classification and the clinical interpretation of effect measures. Optimal stratification is the preferred method for dichotomizing continuous variables, as tertiles, quartiles and means lack sufficient sensitivity to allow the assessment of a variable's true prognostic value. 22 Optimal stratification is a statistical method similar to receiver operator curve analysis and is able to find the most significant cut-off for a continuous variable with respect to survival, based on log rank statistics. 22 Sex-specific cut-offs were determined for the L3 muscle index, and these cut-offs were subsequently used to categorize patients into low skeletal muscle mass and normal skeletal muscle mass groups. 
RESULTS
A total of 129 patients were identified as having undergone major hepatectomy for PHC during the study period. In 29 patients (22.5%) no adequate preoperative staging CT scan for skeletal muscle mass assessment was available in the radiology information system. In this group of patients, the abdomen had not been scanned through the L3 level, CT scans could not be retrieved from the system or staging had been performed using other imaging modalities such as magnetic resonance imaging. These cases were therefore excluded from further analysis ( Table S1 , available online at the publishers' website). Of the 100 remaining patients, 64 (64.0%) were male and 36 (36.0%) were female. Mean ± standard deviation (SD) L3 muscle indices were 47.65 ± 6.38 cm 2 /m 2 in males and 40.74 ± 6.49 cm 2 /m 2 in females (P < 0.001).
Low and normal skeletal muscle mass groups
Sex-specific cut-off values for L3 muscle mass indices were determined at 46.8 cm 2 /m 2 for males and 39.1 cm 2 /m 2 for females. Using these cut-offs, 42 patients (42.0%) were identified as having low skeletal muscle mass. The time interval between muscle mass measurements on CT and surgery did not differ between the low and normal skeletal muscle mass groups (median: 39 days versus 42 days; P = 0.610). The clinicopathological characteristics of patients in both groups are listed in Table 1 . Lower BMI was observed in patients with low skeletal muscle mass. The majority of patients with low muscle mass were of normal weight. Only four of 42 (9.5%) patients with low muscle mass were defined as cachectic and none of the patients with normal muscle mass fulfilled these criteria. 7 Seventeen patients in the cohort (17.0%) were identified as overweight or obese (BMI ≥25 kg/m 2 ) and as having low muscle mass. Other preoperative patient characteristics did not differ between patients with, respectively, low and normal skeletal muscle mass. Furthermore, there were no significant differences between the groups in prognostic tumor-related factors. Mann-Whitney U-test; c One patient in the normal muscle mass group and one in the low muscle mass group underwent a central resection. Statistical tests were performed using the chi-squared test or Fisher's exact test or as indicated otherwise. ASA American Society of Anesthesiologists; BMI body mass index; CA 19-9 cancer antigen 19-9; CRP C-reactive protein; N1 positive lymph node; R0 negative margin; SD standard deviation; TNM tumor-node-metastasis (stage defined by 7th edition of American Joint Committee on Cancer).
Postoperative morbidity
Overall complications (Clavien-Dindo Grade III and higher) in the 30-day postoperative period or during the hospital stay showed a trend towards a higher incidence in patients with low skeletal muscle mass (n = 28, 66.7%) compared with patients with normal muscle mass (n = 28, 48.3%) (P = 0.067). An overview of postoperative complications is shown in Table 2 . Incidences of sepsis (or septic shock) and liver failure (ISGLS grade B or higher) differed between the patient groups. A total of 15 patients developed sepsis (or septic shock) in the postoperative period; these included three patients (5.2%) in the normal muscle mass group and 12 patients (28.6%) in the low muscle mass group (P = 0.002). Twenty-four patients developed liver failure (ISGLS grade B or higher), including nine patients (15.5%) in the normal skeletal muscle mass group and 15 (35.7%) in the low muscle mass group (P = 0.020). On multivariable analysis, low skeletal muscle mass showed an association with postoperative morbidity of borderline significance (P = 0.070) ( Table 3) . Because of the low number of events, multivariable analysis for the risk factors of sepsis and liver failure was not considered to be feasible. 
Postoperative mortality
Seventeen patients (17.0%) in the selected cohort died within the 90-day postoperative period or during the index hospital stay. Ninety-day postoperative mortality was higher among patients with low skeletal muscle mass (28.6% versus 8.6%; P = 0.009). Other factors associated with postoperative death in univariable analysis were age of >65 years (P = 0.022) and perioperative blood transfusion (P < 0.001) ( Table 4) . Because of the low number of events, multivariable analysis was not considered possible. Among patients with low muscle mass, those who died within the 90-day postoperative period were older (median age: 67 years versus 61 years; P = 0.029) and had higher rates of preoperative cholangitis (83.3% versus 35.7%; P = 0.014) and perioperative blood transfusion (100% versus 63.3%; P = 0.018). Further, a trend towards more extended hepatectomies (66.7% versus 37.7%; P = 0.098) was noted in these patients. 
CHAPTER 6

Survival
Median follow-up among patients who were alive at follow-up was 28 months (range: 2-122 months).
The median overall survival of the total cohort was 36.7 months. Overall survival was shorter in the low skeletal muscle mass group in univariable analysis (22.8 months versus 47.5 months; P = 0.014) (Figure 2) . Corresponding estimated 5-year survival rates in the low and normal skeletal muscle mass groups were 20.3% and 36.2%, respectively. Disease recurrence was noted in 34 patients (34.0%). Median disease-free survival did not differ between patients with, respectively, low and normal skeletal muscle mass (43.3 months versus 39.8 months; P = 0.748). After adjustment for potential and known predictors of survival in multivariable analysis, low skeletal muscle mass remained independently associated with poor overall survival [adjusted hazard ratio (HR) 2.02, 95%
confidence interval (CI) 1.12-3.65; P = 0.020] ( Table 5 ). When postoperative deaths were excluded, low muscle mass was still an independent predictor of worse survival (HR 2.02, 95% CI 1.04-3.92; P = 0.037). The combination of low muscle mass and overweight/obesity was not independently associated with poor survival. 
DISCUSSION
The present study shows that low skeletal muscle mass as defined by our cholangiocarcinomaspecific cut-off, was present in 42% of patients with resectable PHC. Low skeletal muscle mass was associated with postoperative sepsis and liver failure, 90-day mortality and overall survival after major liver resection.
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Low skeletal muscle mass has been recognized as a predictor of postoperative morbidity and mortality in liver transplantation, as well as in several other gastrointestinal cancers, including hepatocellular carcinoma, 1, 6 colorectal liver metastases 3,5 and pancreatic carcinoma, 2 Previous studies related low muscle mass to an increased rate of postoperative infectious complications, including sepsis and wound infections. 27-29 Reisinger et al. assessed the combined effect of low skeletal muscle mass and a lower nutritional and frailty status, and confirmed an associated risk for sepsis. 4 High expression of pro-inflammatory cytokines [e.g. interleukin-1β (IL-1β) and IL-6] in low skeletal muscle mass and cancer cachexia may induce this pro-inflammatory state and may increase the risk for infectious complications. 30 Septic complications are of particular relevance in patients with PHC, as concomitant biliary obstruction predisposes patients to cholangitis and secondary infections. Similarly to studies in colorectal cancer and liver transplantation for benign disease, the present authors observed a higher rate of septic complications (28.6% in patients with low muscle mass versus 5.2% in patients with normal muscle mass) after liver resection for PHC. An association between lower muscle mass and infectious complications was further suggested by a higher rate of preoperative cholangitis of borderline significance. Nonetheless, the temporal sequence of this association remains uncertain: cholangitis may have caused muscle wasting, or patients with lower muscle mass may be at higher risk for preoperative cholangitis. Furthermore, a higher rate of postoperative liver failure was observed in the low muscle mass group (35.7% versus 15.5%).
Overall, skeletal muscle mass showed an association with morbidity of only borderline significance, which may be partly explained by a lack of sufficient statistical power. Skeletal muscle mass showed a significant association with postoperative 90-day mortality in univariable analysis, although the statistical power of the present data may be insufficient to confirm this result in multivariable analysis.
Nonetheless, these results warrant the assessment of low skeletal muscle mass as a risk factor prior to liver surgery in PHC.
The negative impact of low skeletal muscle mass on survival following surgery has also been shown in other hepatobiliary diseases, including HCC. 1, 6 The present study found an effect on survival after liver resection for PHC that was comparable with the effects of resection margin status, lymph node status and tumor differentiation grade. The majority of patients with lower muscle mass did not meet the defined criteria for cancer cachexia, but were simply individuals who had demonstrated lower skeletal muscle mass prior to surgery. Interestingly, even in the absence of severe cancerrelated wasting, CT assessment of skeletal muscle mass showed prognostic value. These results underscore the importance of this patient-related factor.
Interest in the assessment of frailty in surgery patients has increased in recent years. Preoperative frailty scores to evaluate the general condition of patients have been developed and have shown associations with postoperative outcomes. 31-33 These scores, however, are mainly based on patient comorbidities and rarely involve nutritional status, although decreased nutritional intake has been shown to have significant negative impact on postoperative mortality. 4 Some scores include surrogates of skeletal muscle mass (anthropometry, weight loss), but many require additional measurements in patients. However, as almost 50% of patients with low muscle mass may not have any weight loss, whether this factor is an adequate surrogate marker of skeletal muscle mass should be questioned. So far, no skeletal muscle mass index has been included in frailty scores. On the basis of the aforementioned studies and the present results, the current authors propose that skeletal muscle mass should be considered a factor in such scores. Of course, whether the inclusion of CT-based muscle measurements is as discriminative as current practice protocols remains to be ascertained. Although some studies have used dual-energy X-ray absorptiometry to determine muscle mass depletion, the quantification of muscle mass at L3 on CT images is straightforward and easily reproducible, and CT scans are usually available in all patients scheduled for surgery. 7, 9, 34 The question of whether skeletal muscle mass can be increased preoperatively remains. A recent study on outcomes after liver transplantation in patients with low muscle mass observed a significant improvement in overall survival with perioperative nutritional therapy, although skeletal muscle mass itself was not increased. 35 Other studies have focused on inhibiting catabolic pathways that promote muscle wasting. In patients with advanced cholangiocarcinoma, the administration of selumetinib, which is an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase and IL-6, led to significant muscle gain in the majority of patients, but no survival benefit was observed.
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It has been suggested that regular exercise prevents frailty and improves skeletal muscle mass and physical function in older patients, 37 but further studies are needed to assess the effects of preoperative training on muscle mass and survival. In general, modulating skeletal muscle mass 6 seems possible and may therefore represent a promising therapy towards improving postoperative outcomes and even lowering health care costs.
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The present study has several limitations. Firstly, the exclusion from analysis of patients without adequate CT scans has presumably resulted in some degree of selection bias, although the comparison of demographics and complications between included and excluded patients revealed only a clinically significant lower number of R0 resections in the latter group (Table S1 ). The process of selecting study subjects from a total cohort of patients with PHC undergoing hepatectomy led to a smaller sample size and lower number of events. The consequent statistical uncertainty may have particularly influenced the analysis of postoperative morbidity, which showed associations with the analysed predictors of only borderline significance. Moreover, the even lower number of events in the analysis of postoperative mortality prevented the performance of multivariable analysis for that endpoint. Secondly, the study was designed to use a disease-specific cut-off for PHC, as others have done previously for various diseases. 5, 8 Previously established cut-offs were found to show an inaccurate fit that would lead to inaccurate effect measurement. This observation may be explained by the inclusion in the present cohort of less overweight patients. Established cut-offs may not be applicable to all cancer populations as a result of clinicopathological differences and the present authors therefore propose that the optimal stratification method be used to investigate a relationship between skeletal muscle mass and postoperative outcome in such instances.
Thirdly, a relatively high 90-day mortality rate (17.0%) was observed in the preselected cohort (especially in individuals with low muscle mass), given that previous results established by the present group had shown postoperative mortality of 7-10%. The latter series, however, also included patients undergoing only local resection of the extrahepatic bile duct. 10 The high mortality rate (28.6%) within the low muscle mass group may have resulted from higher age, the presence of preoperative cholangitis and more extensive resections in these diseased patients.
Finally, as biliary drainage has been shown to increase nutritional status, it may also indirectly influence preoperative skeletal muscle mass. 39 Standard measurement of skeletal muscle mass status on post-drainage CT scans ensured the standardization of the current analysis. However, the effect of biliary drainage on skeletal muscle mass was not measured because adequate predrainage scans were not available.
To conclude, the present study shows that low skeletal muscle mass has a negative impact on shortand long-term outcomes after hepatectomy for PHC. Therefore, measurement of skeletal muscle mass should be considered in the preoperative risk assessment of patients with PHC. Preoperative amplification of skeletal muscle mass in patients with low muscle mass, using nutritional intervention and/or exercise, potentially improves postoperative outcomes.
